MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines-Reference-Cited by-同舟云学术

MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines

Published:2011-06 Issue:85 Volume:3 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Khurana Surender¹,Verma Nitin¹,Yewdell Jonathan W.²,Hilbert Anne Katrin³,Castellino Flora⁴,Lattanzi Maria⁴,Del Giudice Giuseppe⁴,Rappuoli Rino⁴,Golding Hana¹

Affiliation:

1. Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA.

2. Laboratory of Viral Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

3. Novartis Vaccines and Diagnostics GmbH, Marburg 35041, Germany.

4. Novartis Vaccines and Diagnostics Research Center, Siena 53100, Italy.

Abstract

Adjuvant use improves the quality and quantity of the immune response to pandemic influenza vaccines.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference47 articles.

1. Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine

2. Safety and Immunogenicity of Multiple and Higher Doses of an Inactivated Influenza A/H5N1 Vaccine

3. Vaccine Adjuvants: Putting Innate Immunity to Work

4. Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in Adults

5. A Novel Influenza A (H1N1) Vaccine in Various Age Groups

Cited by 308 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute and persistent responses after H5N1 vaccination in humans;Cell Reports;2024-09

2. Immunometabolic Regulation of Vaccine-Induced Antibody Responses in Aging Mice;Vaccines;2024-08-26

3. Immunogenicity and safety of an Entamoeba histolytica adjuvanted protein vaccine candidate (LecA+GLA-3M-052 liposomes) in rhesus macaques;Human Vaccines & Immunotherapeutics;2024-08

4. Aluminum oxyhydroxide-Poly(I:C) combination adjuvant with balanced immunostimulatory potentials for prophylactic vaccines;Journal of Controlled Release;2024-08

5. Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus;Nature Medicine;2024-07-16